Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019

Stacie B Dusetzina; Haiden A Huskamp; Nancy L Keating

doi:10.1001/jama.2019.4492

Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019

JAMA. 2019 May 28;321(20):2025-2027. doi: 10.1001/jama.2019.4492.

Authors

Stacie B Dusetzina¹, Haiden A Huskamp², Nancy L Keating²

Affiliations

¹ Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
² Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Abstract

This study describes point-of-sale prices for orally administered anticancer drugs offered through Medicare Part D and out-of-pocket changes in spending as a result of decreasing coinsurance and price changes between 2010 and 2019.

Publication types

Letter

MeSH terms

Administration, Oral
Antineoplastic Agents / economics*
Formularies as Topic
Health Expenditures / statistics & numerical data*
Medicare Part D / economics*
Prescription Drugs / economics
Prescription Fees / statistics & numerical data*
United States

Substances

Antineoplastic Agents
Prescription Drugs